Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.60 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3931386 | 0.95 | SMN1; SMN2 (0.62) | CYP1A2CYP2C19SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL4636472 | 0.95 | SMN1; SMN2 (0.62) | CYP1A2CYP2C19SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2199922 | 0.94 | CYP1A2 (0.60) | CYP1A2CYP2C19SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL13879748 | 0.88 | SMN1; SMN2 (0.54) | CYP1A2CYP2C19SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL8229093 | 0.88 | CYP1A2 (0.59) | CYP1A2CYP2C19SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL9529235 | 0.87 | CYP1A2 (0.51) | CYP1A2CYP2C19SMN1; SMN2RAB9ANPC1 | |
| Bromide SCHEMBL3599553 | 0.87 | CYP1A2 (0.58) | CYP1A2CYP2C19SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL10995722 | 0.87 | CYP1A2 (0.51) | CYP1A2CYP2C19SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL3382178 | 0.86 | CYP1A2 (0.48) | CYP1A2CYP2C19SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL4133144 | 0.86 | CYP1A2 (0.51) | CYP1A2CYP2C19SMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570648-B2 | 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer | LES LABORATOIRES SERVIER (FR) | 2026-03-10 | — | — | US | disclosed |
| CN-114450283-B | 3, 6-Diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their use as pro-apoptotic agents | 法国施维雅药厂 | 2024-05-07 | — | — | CN | disclosed |
| CN-114450284-B | 6, 7-Dihydro-5H-pyrido [2,3-C ] pyridazine derivatives as BCL-XL protein inhibitors | 法国施维雅药厂 | 2024-05-07 | — | — | CN | disclosed |
| EP-4003989-B1 | 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER | SERVIER LAB (FR) | 2023-12-27 | — | — | EP | disclosed |
| US-20230310640-A1 | PYRROLOBENZODIAZEPINE DERIVATIVE AND LIGAND-LINKER CONJUGATE THEREOF | LEGOCHEM BIOSCIENCES, INC. (KR) | 2023-10-05 | — | — | US | disclosed |
| CN-116768883-A | Pyrimido aromatic ring compounds and application thereof in medicines | 广东东阳光药业股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2023134765-A1 | FIVE-MEMBERED-RING-CONTAINING DERIVATIVES, PREPARATION METHOD THEREFOR, AND USES THEREOF | 上海翰森生物医药科技有限公司 | 2023-07-20 | — | — | WO | disclosed |
| US-20220363677-A1 | 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER | VERNALIS (R&D) LTD (GB) | 2022-11-17 | — | — | US | disclosed |
| EP-4003989-A1 | 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER | Les Laboratoires Servier (FR) | 2022-06-01 | — | — | EP | disclosed |
| US-20210238187-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | WILLIAM MARSH RICE UNIVERSITY (US) | 2021-08-05 | — | — | US | disclosed |
| US-20030220337-A1 | Seleno compounds containing nitrone moiety, their preparation and their therapeutic uses | SAM-SUNG ELECTRONICS CO., LTD. (KR) | 2003-11-27 | — | — | US | disclosed |
| EP-1112275-B1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS INC (US) | 2003-07-30 | — | — | EP | disclosed |
| WO-2003010154-A1 | SELENO COMPOUNDS CONTAINING NITRONE MOIETY, THEIR PREPARATION AND THEIR THERAPEUTIC USES | SAMSUNG ELECTRONICS CO. LTD. (KR) | 2003-02-06 | — | — | WO | disclosed |
| US-6489476-B1 | FRUCTOSE-1,6-BISPHOSPHATASE ENZYME INHIBITORS ARE USEFUL IN THE TREATMENT OF DIABETES AND OTHER CONDITIONS ASSOCIATED WITH ELEVATED BLOOD GLUCOSE OR EXCESS GLYCOGEN STORAGE. | METABASIS THERAPEUTICS, INC. | 2002-12-03 | — | — | US | disclosed |
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | METABASIS THERAPEUTICS, INC. | 2002-11-21 | — | — | US | disclosed |
| EP-1143955-A3 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| EP-1143955-A2 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| EP-1112275-A1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | Metabasis Therapeutics, Inc. (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000038666-A2 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000014095-A1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS, INC. (US) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220337-A1 | Seleno compounds containing nitrone moiety, their preparation and their therapeutic uses | GPX4, GPX1, LPO | CYP1A2 2908/4885CYP2C19 3821/4885SMN1; SMN2 39/4885 |
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | FBP1, PFKFB1, G6PC1 | CYP1A2 2039/4885CYP2C19 920/4885SMN1; SMN2 2797/4885 |
| US-12570648-B2 | 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer | BCOR, BCL2A1, BAK1 | CYP1A2 584/4885CYP2C19 2423/4885SMN1; SMN2 3990/4885 |
| US-20210238187-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | EPOR, EZR, CD47 | CYP1A2 575/4885CYP2C19 244/4885SMN1; SMN2 2194/4885 |
| US-20220363677-A1 | 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER | BAK1, BCL2, BCL2A1 | CYP1A2 238/4885CYP2C19 1301/4885SMN1; SMN2 4155/4885 |
| US-20230310640-A1 | PYRROLOBENZODIAZEPINE DERIVATIVE AND LIGAND-LINKER CONJUGATE THEREOF | BCR, PDCD1LG2, PRLHR | CYP1A2 1022/4885CYP2C19 342/4885SMN1; SMN2 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.